These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27514012)

  • 1. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
    Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
    Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Garin E; Rolland Y; Edeline J
    Semin Nucl Med; 2019 May; 49(3):218-226. PubMed ID: 30954188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.
    Garin E; Lenoir L; Edeline J; Laffont S; Mesbah H; Porée P; Sulpice L; Boudjema K; Mesbah M; Guillygomarc'h A; Quehen E; Pracht M; Raoul JL; Clement B; Rolland Y; Boucher E
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1057-68. PubMed ID: 23613103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
    Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
    Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
    Palard X; Edeline J; Rolland Y; Le Sourd S; Pracht M; Laffont S; Lenoir L; Boudjema K; Ugen T; Brun V; Mesbah H; Haumont LA; Loyer P; Garin E
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.